作者: Markus Krane , Marcus-André Deutsch , Rüdiger Lange , Stefanie A. Doppler
DOI: 10.3978/J.ISSN.2072-1439.2013.08.71
关键词:
摘要: Cardiovascular disease (CVD) continues to be one of the main causes death in western world. A high burden and costs for healthcare systems claim novel therapeutic strategies besides current conventional medical care. One decade ago first clinical trials addressing stem cell based therapies as a potential alternative strategy myocardial regeneration repair. Besides bone marrow derived cells (BMCs), adult from adipose or cardiac tissue have been used studies with inconsistent results. Although outcomes terms safety feasibility are generally encouraging, functional improvements were mostly disappointingly low failed reach expectations. In future, new concepts regeneration, especially concerning recovery cardiomyocyte loss, developed. Transplantation progenitor populations “true” regenerative potential, direct reprogramming scar into myocardium, engineering stimulation endogenous repair by pharmacological agents conceivable. This review summarizes evidence discusses future improve outcomes.